Amiodarone, the generic name for Corderone®or Pacerone®, is an antiarrhythmic drug intended for use in the treatment of ventricular tachycardia (v-tach). Although this drug is only approved by the FDA for this limited use, physicians routinely prescribe the drug off-label for use in the treatment of routine atrial fibrillation (a-fib). The use of Amiodarone causes serious side effects and causes pulmonary fibrosis in up to 17% of patients who use the drug, resulting in death for many.
If informed of such a high risk of complications most people would not use the drug but would opt for less dangerous treatment options. The manufacturers of the drug have engaged in a coordinated campaign to promote off-label uses without delivery of the government-required warnings.
Trial Attorneys Texas has been active in national Amiodarone litigation for many years and Jay English is on the committee coordinating a national litigation strategy.